Subversive Acquisition LP Announces InterCure’s Letter of Intent Relating to the Acquisition of a Multi-National Medical Cannabis Producer, Better Holdings InterCure Signs Letter of Intent with Cann Pharmaceutical Ltd. Acquisition Strengthens InterCure’s Position as the Largest Cannabis Company Outside of North America TORONTO, April 05, 2021 ...

Subversive Acquisition LP Announces InterCure’s Expansion in Europe InterCure to expand its operations into Austria and Luxembourg Medicann, InterCure’s JV Partner, has committed a €10 million investment into InterCure's Austrian subsidiary Transaction approved by...

Subversive Acquisition LP Highlights InterCure’s Accelerated Growth as the Leading Israeli Cannabis Company InterCure, dba Canndoc, Announces Record-Breaking Q4 Results with Positive EBITDA and Cash Flow InterCure Acquires Four New Medical Cannabis Pharmacies and Increases 2021 Target to 10 Retail...

Circulation: Heart Failure Publishes Clinical Study of InterCure's RESPeRATE Device LOD, Israel, Oct. 7, 2008 (GLOBE NEWSWIRE) -- InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE:INCR), today announced that Circulation: Heart Failure, a...